first tirzepatide injection tryeden Europe Tirzepatide | DirectMeds

The long and short of it is the GLP-1 receptor agonists have looked so good for CV outcomes and

However, the approach to stopping should still be carefully managed by your healthcare team

The SELECT trial (NEJM, 2023) demonstrated that semaglutide 2.4mg reduced major adverse cardiovascular events (MACE) by 20% in over 17,000 patients with overweight/obesity and established cardiovascular disease, without diabetes

Semaglutide slows this process down

Analysts at Goldman Sachs predict 2026 will be a pivotal year for the development of the obesity market with the launch of the Novo and Lilly pills, potentially significantly increasing the addressable population for obesity medications

When genetic testing is unnecessary Most people do not need RET genetic testing before starting tirzepatide